Celldex Therapeutics shares are trading lower after the company reported that the Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis did not meet its primary endpoint. Also, Canaccord Genuity lowered its price target on the stock from $62 to $60.